REPORT ID 6516

United States Friedreich Ataxia Drug Market Report 2017

Publish Date
26-Dec-17
Pages
112
Format
Electronic (PDF)

In this report, the United States Friedreich Ataxia Drug market is valued at USD XX million in 2016 and is expected to reach USD XX million by the end of 2022, growing at a CAGR of XX% between 2016 and 2022.

Geographically, this report splits the United States market into seven regions:
    The West
    Southwest
    The Middle Atlantic
    New England
    The South
    The Midwest
with sales (volume), revenue (value), market share and growth rate of Friedreich Ataxia Drug in these regions, from 2012 to 2022 (forecast).

United States Friedreich Ataxia Drug market competition by top manufacturers/players, with Friedreich Ataxia Drug sales volume, price, revenue (Million USD) and market share for each manufacturer/player; the top players including
    Adverum Biotechnologies Inc
    BioMarin Pharmaceutical Inc.
    Biovista Inc.
    Cardero Therapeutics Inc
    Catabasis Pharmaceuticals, Inc.
    Forward Pharma A/S
    Ixchel Pharma LLC
    Pfizer Inc
    ProQR Therapeutics NV
    RaNA Therapeutics Inc
    Reata Pharmaceuticals Inc
    Retrotope Inc
    Shire Plc
    STATegics Inc
    Voyager Therapeutics Inc

On the basis of product, this report displays the production, revenue, price, market share and growth rate of each type, primarily split into
    ADVM-063
    AGIL-FA
    BHV-4157
    BVA-202
    Others
On the basis on the end users/applications, this report focuses on the status and outlook for major applications/end users, sales volume, market share and growth rate for each application, including
    Clinic
    Hospital
    Others

If you have any special requirements, please let us know and we will offer you the report as you want.

 
			   
Table of Contents

United States Friedreich Ataxia Drug Market Report 2017
1 Friedreich Ataxia Drug Overview
    1.1 Product Overview and Scope of Friedreich Ataxia Drug
    1.2 Classification of Friedreich Ataxia Drug by Product Category
        1.2.1 United States Friedreich Ataxia Drug Market Size (Sales Volume) Comparison by Type (2012-2022)
        1.2.2 United States Friedreich Ataxia Drug Market Size (Sales Volume) Market Share by Type (Product Category) in 2016
        1.2.3 ADVM-063
        1.2.4 AGIL-FA
        1.2.5 BHV-4157
        1.2.6 BVA-202
        1.2.7 Others
    1.3 United States Friedreich Ataxia Drug Market by Application/End Users
        1.3.1 United States Friedreich Ataxia Drug Market Size (Consumption) and Market Share Comparison by Application (2012-2022)
        1.3.2 Clinic
        1.3.3 Hospital
        1.3.4 Others
    1.4 United States Friedreich Ataxia Drug Market by Region
        1.4.1 United States Friedreich Ataxia Drug Market Size (Value) Comparison by Region (2012-2022)
        1.4.2 The West Friedreich Ataxia Drug Status and Prospect (2012-2022)
        1.4.3 Southwest Friedreich Ataxia Drug Status and Prospect (2012-2022)
        1.4.4 The Middle Atlantic Friedreich Ataxia Drug Status and Prospect (2012-2022)
        1.4.5 New England Friedreich Ataxia Drug Status and Prospect (2012-2022)
        1.4.6 The South Friedreich Ataxia Drug Status and Prospect (2012-2022)
        1.4.7 The Midwest Friedreich Ataxia Drug Status and Prospect (2012-2022)
    1.5 United States Market Size (Value and Volume) of Friedreich Ataxia Drug (2012-2022)
        1.5.1 United States Friedreich Ataxia Drug Sales and Growth Rate (2012-2022)
        1.5.2 United States Friedreich Ataxia Drug Revenue and Growth Rate (2012-2022)

2 United States Friedreich Ataxia Drug Market Competition by Players/Suppliers
    2.1 United States Friedreich Ataxia Drug Sales and Market Share of Key Players/Suppliers (2012-2017)
    2.2 United States Friedreich Ataxia Drug Revenue and Share by Players/Suppliers (2012-2017)
    2.3 United States Friedreich Ataxia Drug Average Price by Players/Suppliers (2012-2017)
    2.4 United States Friedreich Ataxia Drug Market Competitive Situation and Trends
        2.4.1 United States Friedreich Ataxia Drug Market Concentration Rate
        2.4.2 United States Friedreich Ataxia Drug Market Share of Top 3 and Top 5 Players/Suppliers
        2.4.3 Mergers & Acquisitions, Expansion in United States Market
    2.5 United States Players/Suppliers Friedreich Ataxia Drug Manufacturing Base Distribution, Sales Area, Product Type

3 United States Friedreich Ataxia Drug Sales (Volume) and Revenue (Value) by Region (2012-2017)
    3.1 United States Friedreich Ataxia Drug Sales and Market Share by Region (2012-2017)
    3.2 United States Friedreich Ataxia Drug Revenue and Market Share by Region (2012-2017)
    3.3 United States Friedreich Ataxia Drug Price by Region (2012-2017)

4 United States Friedreich Ataxia Drug Sales (Volume) and Revenue (Value) by Type (Product Category) (2012-2017)
    4.1 United States Friedreich Ataxia Drug Sales and Market Share by Type (Product Category) (2012-2017)
    4.2 United States Friedreich Ataxia Drug Revenue and Market Share by Type (2012-2017)
    4.3 United States Friedreich Ataxia Drug Price by Type (2012-2017)
    4.4 United States Friedreich Ataxia Drug Sales Growth Rate by Type (2012-2017)

5 United States Friedreich Ataxia Drug Sales (Volume) by Application (2012-2017)
    5.1 United States Friedreich Ataxia Drug Sales and Market Share by Application (2012-2017)
    5.2 United States Friedreich Ataxia Drug Sales Growth Rate by Application (2012-2017)
    5.3 Market Drivers and Opportunities

6  United States Friedreich Ataxia Drug Players/Suppliers Profiles and Sales Data
    6.1 Adverum Biotechnologies Inc
        6.1.1 Company Basic Information, Manufacturing Base and Competitors
        6.1.2 Friedreich Ataxia Drug Product Category, Application and Specification
            6.1.2.1 Product A
            6.1.2.2 Product B
        6.1.3 Adverum Biotechnologies Inc Friedreich Ataxia Drug Sales, Revenue, Price and Gross Margin (2012-2017)
        6.1.4 Main Business/Business Overview
    6.2 BioMarin Pharmaceutical Inc.
        6.2.2 Friedreich Ataxia Drug Product Category, Application and Specification
            6.2.2.1 Product A
            6.2.2.2 Product B
        6.2.3 BioMarin Pharmaceutical Inc. Friedreich Ataxia Drug Sales, Revenue, Price and Gross Margin (2012-2017)
        6.2.4 Main Business/Business Overview
    6.3 Biovista Inc.
        6.3.2 Friedreich Ataxia Drug Product Category, Application and Specification
            6.3.2.1 Product A
            6.3.2.2 Product B
        6.3.3 Biovista Inc. Friedreich Ataxia Drug Sales, Revenue, Price and Gross Margin (2012-2017)
        6.3.4 Main Business/Business Overview
    6.4 Cardero Therapeutics Inc
        6.4.2 Friedreich Ataxia Drug Product Category, Application and Specification
            6.4.2.1 Product A
            6.4.2.2 Product B
        6.4.3 Cardero Therapeutics Inc Friedreich Ataxia Drug Sales, Revenue, Price and Gross Margin (2012-2017)
        6.4.4 Main Business/Business Overview
    6.5 Catabasis Pharmaceuticals, Inc.
        6.5.2 Friedreich Ataxia Drug Product Category, Application and Specification
            6.5.2.1 Product A
            6.5.2.2 Product B
        6.5.3 Catabasis Pharmaceuticals, Inc. Friedreich Ataxia Drug Sales, Revenue, Price and Gross Margin (2012-2017)
        6.5.4 Main Business/Business Overview
    6.6 Forward Pharma A/S
        6.6.2 Friedreich Ataxia Drug Product Category, Application and Specification
            6.6.2.1 Product A
            6.6.2.2 Product B
        6.6.3 Forward Pharma A/S Friedreich Ataxia Drug Sales, Revenue, Price and Gross Margin (2012-2017)
        6.6.4 Main Business/Business Overview
    6.7 Ixchel Pharma LLC
        6.7.2 Friedreich Ataxia Drug Product Category, Application and Specification
            6.7.2.1 Product A
            6.7.2.2 Product B
        6.7.3 Ixchel Pharma LLC Friedreich Ataxia Drug Sales, Revenue, Price and Gross Margin (2012-2017)
        6.7.4 Main Business/Business Overview
    6.8 Pfizer Inc
        6.8.2 Friedreich Ataxia Drug Product Category, Application and Specification
            6.8.2.1 Product A
            6.8.2.2 Product B
        6.8.3 Pfizer Inc Friedreich Ataxia Drug Sales, Revenue, Price and Gross Margin (2012-2017)
        6.8.4 Main Business/Business Overview
    6.9 ProQR Therapeutics NV
        6.9.2 Friedreich Ataxia Drug Product Category, Application and Specification
            6.9.2.1 Product A
            6.9.2.2 Product B
        6.9.3 ProQR Therapeutics NV Friedreich Ataxia Drug Sales, Revenue, Price and Gross Margin (2012-2017)
        6.9.4 Main Business/Business Overview
    6.10 RaNA Therapeutics Inc
        6.10.2 Friedreich Ataxia Drug Product Category, Application and Specification
            6.10.2.1 Product A
            6.10.2.2 Product B
        6.10.3 RaNA Therapeutics Inc Friedreich Ataxia Drug Sales, Revenue, Price and Gross Margin (2012-2017)
        6.10.4 Main Business/Business Overview
    6.11 Reata Pharmaceuticals Inc
    6.12 Retrotope Inc
    6.13 Shire Plc
    6.14 STATegics Inc
    6.15 Voyager Therapeutics Inc

7 Friedreich Ataxia Drug Manufacturing Cost Analysis
    7.1 Friedreich Ataxia Drug Key Raw Materials Analysis
        7.1.1 Key Raw Materials
        7.1.2 Price Trend of Key Raw Materials
        7.1.3 Key Suppliers of Raw Materials
        7.1.4 Market Concentration Rate of Raw Materials
    7.2 Proportion of Manufacturing Cost Structure
        7.2.1 Raw Materials
        7.2.2 Labor Cost
        7.2.3 Manufacturing Expenses
    7.3 Manufacturing Process Analysis of Friedreich Ataxia Drug

8 Industrial Chain, Sourcing Strategy and Downstream Buyers
    8.1 Friedreich Ataxia Drug Industrial Chain Analysis
    8.2 Upstream Raw Materials Sourcing
    8.3 Raw Materials Sources of Friedreich Ataxia Drug Major Manufacturers in 2016
    8.4 Downstream Buyers

9 Marketing Strategy Analysis, Distributors/Traders
    9.1 Marketing Channel
        9.1.1 Direct Marketing
        9.1.2 Indirect Marketing
        9.1.3 Marketing Channel Development Trend
    9.2 Market Positioning
        9.2.1 Pricing Strategy
        9.2.2 Brand Strategy
        9.2.3 Target Client
    9.3 Distributors/Traders List

10 Market Effect Factors Analysis
    10.1 Technology Progress/Risk
        10.1.1 Substitutes Threat
        10.1.2 Technology Progress in Related Industry
    10.2 Consumer Needs/Customer Preference Change
    10.3 Economic/Political Environmental Change

11 United States Friedreich Ataxia Drug Market Size (Value and Volume) Forecast (2017-2022)
    11.1 United States Friedreich Ataxia Drug Sales Volume, Revenue Forecast (2017-2022)
    11.2 United States Friedreich Ataxia Drug Sales Volume Forecast by Type (2017-2022)
    11.3 United States Friedreich Ataxia Drug Sales Volume Forecast by Application (2017-2022)
    11.4 United States Friedreich Ataxia Drug Sales Volume Forecast by Region (2017-2022)

12 Research Findings and Conclusion

13 Appendix
    13.1 Methodology/Research Approach
        13.1.1 Research Programs/Design
        13.1.2 Market Size Estimation
        13.1.3 Market Breakdown and Data Triangulation
    13.2 Data Source
        13.2.1 Secondary Sources
        13.2.2 Primary Sources
    13.3 Disclaimer